Article Information
History
- June 1, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jin Young Ahn, MD1,*,
- Jeongsoo Lee, MD2,*,
- You Suk Suh, PhD3,*,
- Young Goo Song, MD, PhD1,
- Yoon-Jeong Choi, MS3,
- Kyoung Hwa Lee, MD1,
- Sang Hwan Seo, PhD4,
- Manki Song, PhD4,
- Jong-Won Oh, PhD5,
- Minwoo Kim, PhD5,
- Han-Yeong Seo, BS5,
- Jeong-Eun Kwak, PhD2,
- Jin Won Youn, PhD3,
- Jung Won Woo, PhD3,
- Eui-Cheol Shin, MD, PhD2,6,
- Su-Hyung Park, PhD2,6,†,
- Young Chul Sung, PhD3,7,† and
- Jun Yong Choi, MD, PhD1,†
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, South Korea
- 2Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, South Korea
- 3Genexine Inc., Seongnam, Gyeonggi-do 463-400, South Korea
- 4International Vaccine Institute, Seoul 08826, South Korea
- 5Department of Biotechnology, Yonsei University, Seoul, South Korea
- 6The Center for Epidemic Preparedness, KAIST, Daejeon 34141, South Korea
- 7Division of Integrative Bioscience and Biotechnology, Pohang University of Science and Technology, Pohang 790-784, South Korea
- ↵† Correspondence to Su-Hyung Park, PhD, Address: Graduate School of Medical Science & Engineering, KAIST, 291 Daehak-ro, Yuseong-gu, Daejeon 34141, South Korea. Tel: +82-42-350-4248, Fax: +82-42-350-4240, Email: park3{at}kaist.ac.kr, Young Chul Sung, PhD, Address: Genexine Inc., 700 Daewangpangyo-ro, Korea Bio ParkBldg. B, Bundang-gu, Seongnam-si, Gyeonggi-do 13488. Tel: +82-31-628-3201, Fax: +82-31-628-3229, Email: ycsung{at}genexine.com, Jun Yong Choi, MD, PhD, Address: Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, South Korea. Tel: +82-2-2228-1974, Fax: +82-2-393-6884, Email: seran{at}yuhs.ac
↵* Contributed equally
Posted June 01, 2021.
Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 years
